NCT00359463View on ClinicalTrials.gov

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 18, 2006

Primary Completion Date

March 7, 2007

Study Completion Date

March 7, 2007

Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
DRUG

eltrombopag

Subjects will be administered a single oral dose of 50 mg eltrombopag.

Trial Locations (5)

2031

GSK Investigational Site, Randwick, Sydney

5000

GSK Investigational Site, Adelaide

8011

GSK Investigational Site, Christchurch

32608

GSK Investigational Site, Gainesville

32809

GSK Investigational Site, Orlando

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY